Emerging pharmacotherapies for diabetic macular edema

Expert Opinion on Emerging Drugs

Volumn 12, Issue 4, 2007, Pages 591-603

  Furlani, Bruno A ^b   Meyer, Carsten H ^a   Rodrigues, Eduardo B ^b   Maia, Mauricio ^b   Farah, Michel E ^b   Penha, Fernando M ^b   Holz, Frank G ^a  

^a UNIVERSITY OF BONN   (Germany)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bevacizumab; Diabetic retinopathy; Macular edema; Ranibizumab; VEGF

Indexed keywords

AMFENAC; ATORVASTATIN; BEVACIZUMAB; BEVASIRANIB SODIUM; CORTICOSTEROID; DEXAMETHASONE; DICLOFENAC; FLUOCINOLONE ACETONIDE; GLYCOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTIC ACID; LIPID; MIDOSTAURIN; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PEGAPTANIB; PEGVISOMANT; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PLACEBO; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RUBOXISTAURIN; SMALL INTERFERING RNA; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VEGF TRAP;

ABSENCE OF SIDE EFFECTS; BLOOD PRESSURE; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; EYE INJURY; FLUORESCENCE ANGIOGRAPHY; GLYCEMIC CONTROL; HEART; HUMAN; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; IRIS DISEASE; KIDNEY; LASER COAGULATION; LENS DISEASE; LIPID BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRURITUS; RETINA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; SKIN INFLAMMATION; STANDARD; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DIABETIC RETINOPATHY; DRUG DESIGN; HUMANS; MACULAR EDEMA; PROTEIN KINASE C; RNA, SMALL INTERFERING; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 36549086584     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.4.591     Document Type: Review

References (116)

1. WILD S, ROGLIC G, GREEN A et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27(5):1047-1053.
2. RYAN SJ, HINTON DR, SCHACHAT AP et al.: Retina (4th Edition). Elsevier Mosby.
3. MEYER CH: Current treatment approaches in diabetic macular edema. Ophthalmologica (2007) 221(2):118-131. • In this comprehensive paper the author overviews the various therapeutic approaches for diabetic macular edema, while the pathogenesis of the disease has been deeply discussed and correlated to the emerging treatments.
4. FERRARA N: Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. (2004) 25:581-611.
5. STEFANSSON E, LANDERS MB: HOW does vitrectomy afFect diabetic macular edema? Am. J. Ophthalmol. (2006) 141:984.
6. STEFANSSON E: The therapeutic effects of retinal laser treatment and vitrectomy: a theory based on oxygen and vascular physiology. Acta Ophthalmol. Scand. (2001) 79:435-440.
7. GREWING R, MESTER U: Early vitrectomy for progressive diabetic proliferations covering the macula. Br. J. Ophthalmol. (1994) 78:433-436.
8. NASRALLAH FP, JALKH AE, VANCOPPENROLLE F et al.: The role of the vitteous in diabetic macular edema. Ophthalmology (1988) 95:1335-1339. • This is one of the earliest publications to describe the role of the vitreous in the pathogenesis of diabetic macular edema.
9. HIKICHI T, FUJIO N, AKIBA Y et al.: Association between the short-term natural history of diabetic macular edema and the vitteomacular relationship in Type 2 diabetes mellitus. Ophthalmology (1997) 104:473-478.
10. DIABETIC RETINOPATHY STUDY RESEARCH GROUP: A modification of the Airlie House classification of diabetic retinopathy. Report 7. Invest. Ophthalmol. Vis. Sci. (1981) 21:210-226.
11. ANTCLIFF RJ, STANFORD MR, CHAUHAN DS et al.: Comparison between optical coherence tomography and fundus fluorescein angiography for the detection of cystoids macular edema in patients with uveitis. Ophthalmology (2000) 107:593-599.
12. EARLY TREATMENT DIABETIC RETINOPATHY STUDY RESEARCH GROUP: Photocoagulation for diabetic macular edema. ETDRS report No 4. Int. Ophthalmol. Clin. (1987) 27:254-264. • In this trial report the group released some of the key results of the very important trial named ETDRS.
13. KLEIN R, KLEIN BEK, MOSS SE et al.: The Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology (1984) 91:1464-1474.
14. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. (1993) 329:977-986. • In this trial report the group released some of the results of the trial named DCCT that demonstrate the efficacy of tight blood glucose to prevent diabetic retinopathy.
15. UK PROSPECTIVE DIABETES STUDY GROUP: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet (1998) 352:837-853.
16. EARLY TREATMENT DIABETIC RETINOPATHY STUDY RESEARCH GROUP: Photocoagulation for DME early treatment diabetic retinopathy study report number 1. Arch. Ophthalmol. (1985) 103:1796-1806.
17. FERRIS FL, PATZ A: Macular edema: a complication of diabetic retinopathy. Surv. Ophthalmol. (1984) 28(Suppl.):452-461.
18. BRESNICK GH: Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology (1983) 90:1301-1317.
19. OLK RJ: Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology (1986) 93:938-950.
20. LAM RF, LAI WW, CHAN WM et al.: Vitrectomy for diabetic macular edema with and without internal limiting membrane removal. Ophthalmologica (2006) 220:206.
21. STEFANSSON E, LANDERS MB: How does vitrectomy affect diabetic macular edema? Am. J. Ophthalmol. (2006) 141:984.
22. YANYALI A, HOROZOGLU F, CELIK E et al.: Long-term outcomes of pats plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina (2007) 27(5):557-566.
23. SHIMONAGANO Y, MAKIUCHI R, MIYAZAKI M et al.: Results of visual acuity and foveal thickness in diabetic macular edema after vitrectomy. Jpn J. Ophthalmol. (2007) 51:204-209.
24. BAHADIR M, ERTAN A, MERTOGLU O: Visual acuity comparison of vitrectomy with and without internal limiting membrane removal in the treatment of diabetic macular edema. Int. Ophthalmol. (2005) 6(1-2):3-8.
25. STOLBA U, BINDER S, GRUBER D et al.: Vitrectomy for persistent diffuse diabetic macular edema. Am. J. Ophthalmol. (2005) 140(2):295-301.
26. ANTONETTI DA, WOLPERT EB, DEMAIO L et al.: Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occluding. J. Neurochem. (2002) 80:667-677.
27. EDELMAN JL, LUTZ D, CASTRO MR: Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp. Eye Res. (2005) 80:249-258.
28. GAO H, QIAO X, GAO R et al.: Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina. Vision Res. (2004) 44:349-356.
29. BROOKS HL, CABALLERO S, NEWELL CK et al.: Vitreous levels of vascular endothelial growth factor and stromal-derived factot 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch. Ophthalmol. (2004) 122:1801- 1807.
30. STELLATO C: Post-transcriptional and non-genomic effects of glucocorticoids. Proc. Am. Thorac. Soc. (2004) 1:255-263.
31. ZHOU ZH, BUBIEN JK: Non-genomic regulation of ENaC by aldosterone. Am. J. Physiol. Cell Physiol. (2001) 281:C1118-C1130.
32. PENFOLD PL, GYORY JF, HUNYOR AB, BILLSON FA: Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. NZ J. Ophthalmol. (1995) 23(4):293-298.
33. MARTIDIS A, DUKER JS, GREENBERG PB et al.: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology (2002) 109(5):920-927.
34. JONAS JB, KREISSIG I, SOFKER A et al.: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch. Ophthalmol. (2003) 121(1):57-61. •• This paper demonstrate the positive role of the cristaline steroid triamcinolone to treat diffuse macular edema.
35. CHIEH JJ, ROTH DB, LIU M et al.: Intravitreal triamcinolone acetonide for diabetic macular edema. Retina (2005) 25(7):828-834.
36. MASSIN P, AUDREN F, HAOUCHINE B et al.: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Preliminary results of a prospective controlled trial. Ophthalmology (2004) 111:218-224.
37. OH JY, SEO JH, AHN JK et al.: Early versus late intravitreal triamcinolone acetonide for macular edema associated with branch retinal vein occlusion. Korean J. Ophthalmol. (2007) 21(1):18-20.
38. KOUTSANDREA C, MOSCHOS MM, BROUZAS D et al.: Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema: optical coherence tomography and multifocal electroretinography study. Retina (2007) 27(2):159-164.
39. MORRISON VL, KOZAK I, LABREE LD et al.: Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology (2007) 114(2):334-339.
40. MOSCHOS MM, BROUZAS D, LOUKIANOU E et al.: Intraocular triamcinolone acetonide for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc. Ophthalmol. (2007) 114(1):1-7.
41. GILLIES MC, SUTTER FK, SIMPSON JM et al.: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology (2006) 113(9):1533-1538.
42. LAM DS, CHAN CK, MOHAMED S et al.: A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br. J. Ophthalmol. (2007) 91(2):199-203.
43. AVITABILE T, LONGO A, REIBALDI A: Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am. J. Ophthalmol. (2005) 140:695-702.
44. QUIRAM PA, GONZALES CR, SCHWARTZ SD: Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol. (2006) 141(3):580-582.
45. KAUSHIK S, GUPTA V, GUPTA A et al.: Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am. J. Ophthalmol. (2004) 137(4):758-760.
46. VIOLA F, MORESCALCHI F, STAURENGHI G: Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch. Ophthalmol. (2006) 124(1):133-134.
47. SMITHEN LM, OBER MD, MARANAN L et al.: Intravitreal triamcinolone acetonide and intraocular pressure. Am. J. Ophthalmol. (2004) 138(5):740-743.
48. THOMPSON JT: Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am. J. Ophthalmol. (2006) 141(4):629-637.
49. WESTFALL AC, OSBORN A, KUHL D et ai.: Acute endophthalmitis incidence: intravitreal Triamcinolone. Arch. Ophthalmol. (2005) 123(8):1075-1077.
50. MOSHFEGHI DM, KAISER PK, SCOTT IU et al.: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol. (2003) 136(5):791-796.
51. NABIH M, PEYMAN GA, TAWAKOL ME et al.: Toxicity of high-dose intravitreal dexamethasone. Int. Ophthalmol. (1991) 15:233-235.
52. KWAK HW, D'AMICO DJ: Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch. Ophthalmol. (1992) 110:259-266.
53. MAXWELL DP Jr, BRENT BD, DIAMOND JG et al.: Effect of intravitreal dexamethasone on ocular histopathology in a rabbit model of endophthalmitis. Ophthalmology (1991) 98:1370-1375.
54. KUPPERMANN BD, BLUMENKRANZ MS, HALLER JA et al.: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. (2007) 125(3):309-317.
55. FLUOCINOLONE ACETONIDE OPHTHALMIC-BAUSCH & LOMB: Fluocinolone acetonide envision TD implant. Drugs RD (2005) 6:116-119.
56. FLUOCINOLONE ACETONIDE IMPLANT STUDY GROUP: Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial. Invest. Ophthalmol. Vis. Sci. (2006) 47:E5442 (Abstract).
57. ADAMIS AP, MILLER JW, BERNAL MT et al.: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. (1994) 118:445-450.
58. AIELLO LP, AVERY RL, ARRIGG PG et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. (1994) 331:1480-1487. • This pioneer report describes the enhanced levels of VEGF in the vitreous of diabetic patients.
59. MALECAZE F, CLAMENS S, SIMORRE-PINATEL V et al.: Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol. (1994) 112:1476-1482.
60. TOLENTINO MJ, MCLEOD DS, TAOMOTO M et al.: Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am. J. Ophthalmol. (2002) 133:373-385.
61. TOLENTINO MJ, MILLER JW, GRAGOUDAS ES et al.: Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 103:1820-1828.
62. QAUM T, XU Q, JOUSSEN AM et al.: VEGF-initiated bloodretinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. (2001) 42:2408-2413.
63. ISHIDA S, USUI T, YAMASHIRO K et al.: VEGF164 is proinflammatory in the diabetic retina. Invest. Ophthalmol. Vis. Sci. (2003) 44:2155-2162.
64. WOOLARD J, WANG WY, BEVAN HS et al.: VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. (2004) 64(21):7822-7835.
65. EMERSON MV, LAUER AK: Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs (2007) 21(4):245-257.
66. CUNNINGHAM ET Jr, ADAMIS AP, ALTAWEEL M et al.: Macugen diabetic retinopathy study group: a Phase II randomized double-masked trial of pegaptanib, an antivascular endothelial gtowth factor aptamer, for diabetic macular edema. Ophthalmology (2005) 112:1747-1757.
67. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
68. ROSENFELD PJ, MOSHFEGHI AA, PULIAFITO CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthal. Surg. Lasers Imaging (2005) 36(4):331-335.
69. ROSENFELD PJ, FUNG AE, PULIAFITO CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthal. Surg. Lasers Imaging (2005) 36(4):336-339.
70. AVERY RL: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (2006) 26(3):352-354.
71. SCHWARTZ SG, HICKEY M, PULIAFITO CA: Bilateral CRAO and CRVO from thrombotic thrombocytopenic purpura: OCT findings and treatment with triamcinolone acetonide and bevacizumab. Ophthalmic. Surg. Lasers Imaging (2006) 37(5):420-422.
72. MASON JO, ALBERT MA, VAIL R: Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina (2006) 26(3):356-357.
73. HARITOGLOU C, KOOK D, NEUBAUER A: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina (2006) 26(9):999-1005.
74. AREVALO JF, FROMOW-GUERRA J, QUIROZ-MERCADO H et al.: Pan-American collaborative retina study group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American collaborative retina study group at 6-month follow-up. Ophthalmology (2007) 114(4):743-750. • This multi-center pan-American group reported the safe and effective application of anti-VEGF Bevacizumab in the therapy of diabetic macular edema.
75. YANYALI A, AYTUG B, HOROZOGLU F, NOHUTCU AF: Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am. J. Ophthalmol. (2007) 144(1):124-126.
76. JANORIA KJ, GUNDA S, BODDU SH, MITRA AK: Novel approaches to retinal drug delivery. Expert Opin. Drug Deliv. (2007) 4:371-388.
77. HEIER JS, ANTOSZYK AN, PAVAN PR et al.: Ranibizumab for treatment of neovascular age-related macular degeneration: a Phase I/II multicenter, controlled, multidose study. Ophthalmology (2006) 113(4):642.E1- E4. (Epub 14 February 2006).
78. BROWN DM, KAISER PK, MICHELS M et al.: ANCHOR study group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. (2006) 355(14):1432-1444.
79. CHUN DW, HEIER JS, TOPPING TM et al.: A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology (2006) 113(10):1706-1712.
80. NGUYEN QD, TATLIPINAR S, SHAH SM et al.: Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol. (2006) 142(6):961-969.
81. NGUYEN QD, SHAH SM, HAFIZ G et al.: CLEAR-AMD 1 study group. A Phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology (2006) 113(9):1522.E1-1522. E14. (Epub 28 July 2006).
82. RUDGE JS, THURSTON G, DAVIS S et al.: VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene-based discovery of the next generation of angiogenesis targets. Cold Spring Harb. Symp. Quant. Biol. (2005) 70:411-418.
83. DO DV, NGUYEN QD, BROWNING DJ et al.: Results of a Phase I study of intravitreal VEGF trap in subjects with diabetic macular edema: the CLEAR-IT DME study. Invest. Ophthalmol. Vis. Sci. (2007) 48:E1430 (Abstract).
84. SHEETZ MJ, KING GL: Molecular understanding of hyperglycemias adverse effects for diabetic complications. JAMA (2002) 288:2579-2588.
85. MELLOR H, PARKER PJ: The extended protein kinase C superfamily. Biochem. J. (1998) 332:281-292.
86. BULLOCK WH, MAGNUSON SR, CHOI S et al.: Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr. Top. Med. Chem. (2002) 2:915-938.
87. AIELLO LP, BURSELL SE, CLERMONT A et al.: Vascular endothelial growth factor induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes (1997) 46:1473-1480.
88. XU X, ZHU Q, XIA X et al.: Blood-retinal barrier breakdown induced by activation of protein kinase C via vasculat endothelial growth factor in streptozotocin-induced diabetic rats. Curr. Eye Res. (2004) 28:251-256.
89. JIROUSEK M, GILLIG J, GONZALEZ C et al.: (S)-13-[(dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13Hdibenzo[e,k]pyrrolo [3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C. J. Med. Chem. (1996) 39:2664-2671.
90. ISHII H, JIROUSEK M, KOYA D et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC inhibitor. Science (1996) 272:728-731.
91. NONAKA A, KIRYU J, TSUJIKAWA A et al.: PKC-β inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest. Ophthalmol. Vis. Sci. (2000) 41:2702-2706.
92. ABIKO T, ABIKO A, CLERMONT A et al.: Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes (2003) 52:829-837.
93. DANIS R, BINGAMAN D, JIROUSEK M, YANG Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC inhibition with LY333531. Invest. Ophthalmol. Vis. Sci. (1998) 39:171-179.
94. THE PKC-DRS STUDY GROUP: The effect of ruboxistaurin on visual loss in patients with moderately severe to vety severe nonproliferative diabetic retinopathy: initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKCDRS) multicenter randomized clinical trial. Diabetes (2005) 54(7):2188-2197.
95. PKC-DRS2 GROUP: Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology (2006) 113(12):2221-2230.
96. THE PKC-DMES STUDY GROUP: Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the tandomized PKC-DMES clinical trial. Arch. Ophthalmol. (2007) 125(3):318-324.
97. PROPPER DJ, MCDONALD AC, MAN A et al.: Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. (2001) 19(5):1485-1492.
98. CAMPOCHIARO PA, C99-PKC412-003 STUDY GROUP: Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci. (2004) 45(3):922-931.
99. SEO M, KWAK N, OZAKI H et al.: Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. J. Pathol. (1999) 154:1743-1753.
100. SIMO R, CARRASCO E, FONOLLOSA A et al.: Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema. Diabetes Care (2007) 30(3):725-727.
101. KIRKEGAARD C, NORGAARD K, SNORGAARD O et al.: Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinol. (Copenh) (1990) 122(6):766-772.
102. HERNAEZ-ORTEGA MC, SOTO-PEDRE E, MARTIN JJ: Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience. Diabetes Res. Clin. Pract. (2004) 64(1):71-72.
103. GROWTH HORMONE ANTAGONIST FOR PROLIFERATIVE DIABETIC RETINOPATHY STUDY GROUP: The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology (2001) 108(12):2266-2272.
104. COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364(9435):685-696.
105. KLEIN BEK, MOSS SE, KLEIN R, SURAWICZ TS: The Wisconsin epidemiologic study of diabetic retinopathy, XII: relationship of serum cholesterol to retinopathy and hard exudates. Ophthalmology (1991) 98:1261-1265.
106. CHEW EY, KLEIN ML, FERRIS FL III: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early treatment diabetic retinopathy study (ETDRS) report 22. Arch. Ophthalmol. (1996) 114(9): 1079-1084.
107. GUPTA A, GUPTA V, THAPAR S, BHANSALI A: Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am. J. Ophthalmol. (2004) 137:675-682.
108. CHRISTOFORIDIS JB, ADAMIS AP, D'AMICO DJ: Medical treatment of diabetic macular edema with rofecoxib. Invest. Ophthalmol. Vis. Sci. (2005) 46:E391 (Abstract).
109. KE TL, GRAFF G, SPELLMAN JM, YANNI JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation (2000) 24(4):371-384.
110. GAMACHE DA, GRAFF G, BRADY MT et al.: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation (2000) 24(4):357-370.
111. KERN TS, MILLER CM, DU Y et al.: Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes (2007) 56(2):373-379. •• This ground-breaking investigative report reveals that topical drug application of an anti-inflammatory drug may influence the progression of diabetic retinopathy.
112. http://www.cdc.gov/diabetes/news/docs/dpp.htm Centers for Disease Control and Prevention. CDCs Diabetes Program - News and Information - Press Releases - (2000).
113. http://www.regeneron.com/company/press_detail.asp?v_c_id=252 REGENERON: Company Information. Press releases (2006).
114. http://www.medicalnewstoday.com/articles/44387.php MediLexicon International Ltd. Acuity Pharmaceuticals Reports Positive Initial Phase II Results For Bevasiranib (Cand5) In Wet AMD (2007).
115. http://www.bioadvance.com/downloads/fact-sheets/ACU_FS_0807.pdf Acuity Pharmaceuticals (2006).
116. http://www.caringfordiabetes.com/ER/Conference Reports/ AAO2006__Las_Vegas/C575BhavsarFuture.cfm The Caring for Diabetes Educational Forum (2007).